Breaking News

Romark Awarded HHS Influenza Contract

To complete development of NT-300

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Romark Laboratories has been awarded a contract with the U.S. Department of Health and Human Services (HHS) to complete the development of NT-300 (nitazoxanide) for acute uncomplicated influenza. The contract, valued at $44 million, will be administered through the Biomedical Advanced Research and Development Authority (BARDA), an agency within the Office of the Assistant Secretary for Preparedness and Response.   BARDA selected Romark for its development plan that includes a novel mechanism of ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters